Skip to main content
SpringerLink
Log in

Type 2 Diabetes and Concomitant Illness

The Prepared Practice

  • Chapter
Type 2 Diabetes Mellitus

Part of the book series: Contemporary Endocrinology ((COE))

  • 3788 Accesses

Summary

Prospective randomized trials have established the importance of glycemic control for the patient with type 2 diabetes with respect to both the outcomes of critical illness treated in the hospital and chronic microvascular complications of diabetes. For other conditions initially recognized in the ambulatory setting, the caregiver is called upon to determine not only whether intensification of antihyperglycemic management is required, but also within what timeframe it must be achieved, and in what setting care will be conducted. Despite the paucity of data on the potential importance of strict glycemic control to concomitant ambulatory conditions other than the classic tissue complications of diabetes, we will attempt to review those conditions for which some evidence exists on the following questions: Does risk of development of the condition correlate with the presence of diabetes? Does risk of development of the condition correlate with glycemic control? Do outcomes of the condition correlate with glycemic control? Do outcomes of the condition correlate with the presence of diabetes? Does the co-morbidity itself affect diabetic control or risk of developing diabetes? Strategies for outpatient care during intercurrent illness are suggested, with remarks about preadmission and postdischarge hospital care.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

References

  1. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995;28(2):103–17.

    PubMed  CAS  Google Scholar 

  2. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352(9131):837–53.

    PubMed  Google Scholar 

  3. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352(9131):854–65.

    PubMed  Google Scholar 

  4. Gaede P, Vedel P, Parving H-H, Pedersen OU. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet 1999;353(9153):617–22.

    PubMed  CAS  Google Scholar 

  5. Gaede P, Vedel P, Larsen N, Jensen GVH, Parving H-H, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348(5):383–93.

    PubMed  Google Scholar 

  6. The Diabetes Control and Complications Trial Research Group (DCCT). The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977–86.

    Google Scholar 

  7. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 2000;342(6):381–9.

    Google Scholar 

  8. The Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 2002;287(19):2563–9.

    Google Scholar 

  9. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) Study. JAMA 2003;290(16):2159–67.

    Google Scholar 

  10. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353(25):2643–53.

    Google Scholar 

  11. Standards of Medical Care in Diabetes – 2008; 31 (Suppl.1):S12–S54.

    Google Scholar 

  12. Abraira C, Colwell JA, Nuttall F, et al. VA Cooperative study on glycemic control and complications in type 2 diabetes: results of the feasibility trial. Diabetes Care 1995;18:1113–23.

    PubMed  CAS  Google Scholar 

  13. Abraira C, Henderson WG, Colwell JA, et al. Response to intensive therapy steps and to glipizide dose in combination with insulin in type 2 diabetes: VA feasibility study on glycemic control and complications (VA CSDM). Diabetes Care 1998;21(4):574–9.

    PubMed  CAS  Google Scholar 

  14. Abraira C, McGuire DK. intensive insulin therapy in patients with type 2 diabetes: implications of the Veterans Affairs (VA CSDM) feasibility trial. Am Heart J 1999;138:360–5.

    Google Scholar 

  15. Duckworth WC, McCarren M, Abraira C. Glucose control and cardiovascular complications: the VA Diabetes Trial. Diabetes Care 2001;24(5):942–5.

    PubMed  CAS  Google Scholar 

  16. Kirkman MS, McCarren M, Shah J, Duckworth W, Abraira C. The association between metabolic control and prevalent macrovascular disease in type 2 diabetes: the VA Cooperative Study in diabetes. J Diabetes Complications 2006;20(2):75–80.

    PubMed  Google Scholar 

  17. Hawkins M, Gabriely I, Wozniak R, Reddy K, Rossetti L, Shamoon H. Glycemic control determines hepatic and peripheral glucose effectiveness in type 2 diabetic subjects. Diabetes 2002;51(7):2179–89.

    PubMed  CAS  Google Scholar 

  18. Cusi K, Maezono K, Osman A, et al. Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle. J Clin Invest 2000;105(3):311–20.

    PubMed  CAS  Google Scholar 

  19. Lin Y, Rajala MW, Berger JP, Moller DE, Barzilai N, Scherer PE. Hyperglycemia-induced production of acute phase reactants in adipose tissue. J Biol Chem 2001;276(45):42077–83.

    PubMed  CAS  Google Scholar 

  20. Esposito K, Nappo F, Marfella R, et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: Role of oxidative stress. Circulation 2002;106:2067–72.

    PubMed  CAS  Google Scholar 

  21. Pantaleo A, Zonszein J. Using insulin as a drug rather than as a replacement hormone during acute illness: a new paradigm. Heart Dis 2003;5(5):323–33.

    PubMed  CAS  Google Scholar 

  22. Vanhorebeek I, Langouche L, Van den Berghe G. Intensive insulin therapy in the intensive care unit: update on clinical impact and mechanisms of action. Endocrine Practice 2006;12 (Supplement 3):14–21.

    PubMed  Google Scholar 

  23. Hotamisligil GS, Murray DL, Choy LN, Spiegelman BM. Tumor necrosis factor alpha inhibits signaling from the insulin receptor. Proc Natl Acad Sci U S A 1994;91(11):4854–8.

    PubMed  CAS  Google Scholar 

  24. Liu YF, Paz K, Herschkovitz A, et al. Insulin stimulates PKCzeta -mediated phosphorylation of insulin receptor substrate-1 (IRS-1). A self-attenuated mechanism to negatively regulate the function of IRS proteins. J Biol Chem 2001;276(17):14,459–65.

    CAS  Google Scholar 

  25. Le Roith D. Molecular mechanisms by which metabolic control may improve outcomes. Endocrine Practice 2004;10 (Suppl 2):57–62.

    PubMed  Google Scholar 

  26. Boden G, She P, Mozzoli M, et al. Free fatty acids produce insulin resistance and activate the proinflammatory nuclear factor-kappa B pathway in rat liver. Diabetes 2005;54(12):3458–65.

    PubMed  Google Scholar 

  27. Dresner A, Laurent D, Marcucci M, et al. Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. J Clin Invest 1999;103(2):253–9.

    PubMed  CAS  Google Scholar 

  28. Lam TK, Yoshii H, Haber CA, et al. Free fatty acid-induced hepatic insulin resistance: a potential role for protein kinase C-delta. Am J Physiol Endocrinol Metab 2002;283(4):E682–91.

    PubMed  CAS  Google Scholar 

  29. Van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in critically ill patients. N Engl J Med 2001;345(19):1359–67.

    PubMed  Google Scholar 

  30. Malmberg K, Ryden L, Hamstent A, et al. Effects of insulin treatment on cause-specific one-year mortality and morbidity in diabetic patients with acute myocardial infarction. Eur Heart J 1996;17(9):1337–44.

    PubMed  CAS  Google Scholar 

  31. Malmberg K. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. BMJ 1997;314(7093):1512–15.

    PubMed  CAS  Google Scholar 

  32. Zerr KJ, Furnary AP, Grunkemeier GL. Glucose control lowers the risk of wound infection in diabetics after open heart operations. Ann Thorac Surg 1997;63:356–61.

    PubMed  CAS  Google Scholar 

  33. Furnary AP, Zerr KJ, Grunkemeier GL, Starr A. Continuous intravenous insulin infusion reduces the incidence of deep sternal wound infection in diabetic patients after cardiac surgical procedures. Ann Thorac Surg 1999;67:352–62.

    PubMed  CAS  Google Scholar 

  34. Furnary AP, Gao G, Grunkemeier GL, et al. Continuous insulin infusion reduces mortality in patients with diabetes undergoing coronary artery bypass grafting. J Thorac Cardiovasc Surg 2003;125(5):1007–21.

    PubMed  CAS  Google Scholar 

  35. Furnary AP, Wu Y, Bookin SO. Effect of hyperglycemia and continuous intravenous insulin infusions on outcomes of cardiac surgical procedures: the Portland diabetic project. Endocr Pract 2004;10(Suppl. 2):21–33.

    Google Scholar 

  36. Van den Berghe G, Wilmer A, Hermans G, et al. Intensive Insulin Therapy in the Medical ICU. N Engl J Med 2006;354(5):449–61.

    PubMed  Google Scholar 

  37. Krinsley JS. Decreased mortality of critically ill patients with the use of an intensive glycemic management protocol. Mayo Clin Proc 2003;78:1471–8.

    PubMed  Google Scholar 

  38. Krinsley JS. Effect of an intensive glucose management protocol on the mortality of critically ill adult patients. Mayo Clin Proc 2004;79:992–1000.

    PubMed  Google Scholar 

  39. Grey NJ, Perdrizet GA. Reduction of nosocomial infections in the surgical intensive-care unit by strict glycemic control. Endocr Pract 2004;10(Suppl. 2):46–52.

    PubMed  Google Scholar 

  40. Furnary AP, Wu Y. Clinical effects of hyperglycemia in the cardiac surgery population: the Portland diabetic project. Endocr Pract 2006;12(Suppl. 3):22–6.

    PubMed  Google Scholar 

  41. ACE/ADA Task Force on Inpatient Diabetes. American College of Endocrinology and American Diabetes Association Consensus Statement on Inpatient Diabetes and Glycemic Control. Endocrine Practice 2006;12 (Supplement 3):3–13.

    Google Scholar 

  42. Mesotten D, Swinnen JV, Vanderhoydonc F, Wouters PJ, Van den Berghe G. Contribution of Circulating Lipids to the Improved Outcome of Critical Illness by Glycemic Control with Intensive Insulin Therapy. J Clin Endocrinol Metab 2004;89(1):219–26.

    PubMed  CAS  Google Scholar 

  43. Malmberg K, Norhammar A, Wedel H, Ryden L. Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: long-term results from the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) study. Circulation 1999;99(20):2626–32.

    PubMed  CAS  Google Scholar 

  44. Umpierrez GE, Isaacs SD, Bazargan N, You X, Thaler LM, Kitabchi AE. Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes. J Clin Endocrinol Metab 2002;87(3):978–82.

    PubMed  CAS  Google Scholar 

  45. Williams LS, Rotich J, Qi R, et al. Effects of admission hyperglycemia on mortality and costs in acute ischemic stroke. Neurology 2002;59(1):67–71.

    PubMed  CAS  Google Scholar 

  46. Bruno A, Levine SR, Frankel MR, et al. Admission glucose level and clinical outcomes in the NINDS rt-PA Stroke Trial. Neurology 2002;59(5):669–74.

    PubMed  CAS  Google Scholar 

  47. Laird AM, Miller PR, Kilgo PD, Meredith JW, Chang MC. Relationship of early hyperglycemia to mortality in trauma patients. J Trauma 2004;56:1058–62.

    PubMed  Google Scholar 

  48. Kosiborod M, Rathore SS, Inzucchi SE, et al. Admission Glucose and Mortality in Elderly Patients Hospitalized With Acute Myocardial Infarction: Implications for Patients With and Without Recognized Diabetes. Circulation 2005;111(23):3078–86.

    PubMed  Google Scholar 

  49. Hirsch IB. Inpatient diabetes: review of data from the cardiac care unit. Endocrine Practice 2006;12(Suppl. 3).

    Google Scholar 

  50. Hirsch IB. Effect of insulin therapy on nonglycemic variables during acute illness. Endocr Pract 2004;10(Suppl. 2):63–70.

    PubMed  Google Scholar 

  51. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999;340(6):448–54.

    PubMed  CAS  Google Scholar 

  52. Dandona P, Aljada A, Mohanty P, et al. Insulin inhibits intranuclear nuclear factor kappaB and stimulates IkappaB in mononuclear cells in obese subjects: evidence for an anti-inflammatory effect? J Clin Endocrinol Metabol 2001;86(7):3257–65.

    CAS  Google Scholar 

  53. Zeng G, Quon MJ. Insulin-stimulated production of nitric oxide is inhibited by wortmannin. Direct measurement in vascular endothelial cells. J Clin Invest 1996;98(4):894–8.

    PubMed  CAS  Google Scholar 

  54. Steinberg HO, Brechtel G, Johnson A, Fineberg N, Baron AD. Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent. A novel action of insulin to increase nitric oxide release. J Clin Invest 1994;94(3):1172–9.

    PubMed  CAS  Google Scholar 

  55. Steinberg HO, Tarshoby M, Monestel R, et al. Elevated circulating free fatty acid levels impair endothelium-dependent vasodilation. J Clin Invest 1997;100(5):1230–9.

    PubMed  CAS  Google Scholar 

  56. Aljada A, Dandona P. Effect of insulin on human aortic endothelial nitric oxide synthase. Metabolism 2000;49(2):147–50.

    PubMed  CAS  Google Scholar 

  57. Alonso D, Radomski MW. Nitric oxide, platelet function, myocardial infarction and reperfusion therapies. Heart Fail Rev 2003;8(1):47–54.

    PubMed  CAS  Google Scholar 

  58. Chaudhuri A, Kanjwal Y, Mohanty P, et al. Insulin-induced vasodilatation of internal carotid artery. Metabolism 1999;48(11):1470–3.

    PubMed  CAS  Google Scholar 

  59. Scherrer U, Randin D, Vollenweider P, Vollenweider L, Nicod P. Nitric oxide release accounts for insulin’s vascular effects in humans. J Clinl Invest 1994;94:2511–15.

    CAS  Google Scholar 

  60. Langouche L, Vanhorebeek I, Vlasselaers D, et al. Intensive insulin therapy protects the endothelium of critically ill patients. J Clin Invest 2005;115(8):2277–86.

    PubMed  Google Scholar 

  61. Pomposelli JJ, Baxter JK, Babineau TJ, et al. Early postoperative glucose control predicts nosocomial infection rate in diabetic patients. J Parenteral & Enteral Nutrition 1998;22(2):77–81.

    CAS  Google Scholar 

  62. Thomas M, Mathew T, Russ G, Rao M, Moran J. Early peri-operative glycaemic control and allograft rejection in patients with diabetes mellitus: a pilot study. Transplantation 2001;72(7):1321–4.

    PubMed  CAS  Google Scholar 

  63. Vriesendorp TM, Morelis QJ, DeVries JH, Legemate DA, Hoekstra JBL. Early post-operative glucose levels are an independent risk factor for infection after peripheral vascular surgery. A retrospective study. Eur J Vasc Endovasc Surg 2004;5:520–5.

    Google Scholar 

  64. Weiser M. Relation between the duration of remission and hyperglycemia in induction chemotherapy for acute lymphocytic leukemia. Cancer 2004;100:1179–85.

    PubMed  CAS  Google Scholar 

  65. Bagdade JD, Root RK, Bulger RJ. Impaired leukocyte function in patients with poorly controlled diabetes. Diabetes 1974;23(1):9–15.

    PubMed  CAS  Google Scholar 

  66. Bagdade JD, Stewart M, Walters E. Impaired granulocyte adherence. A reversible defect in host defense in patients with poorly controlled diabetes. Diabetes 1978;27(6):677–81.

    PubMed  CAS  Google Scholar 

  67. Naghibi M, Smith RP, Baltch AL, et al. The effect of diabetes mellitus on chemotactic and bactericidal activity of human polymorphonuclear leukocytes. Diabetes Res Clin Pract 1987;4:27–35.

    PubMed  CAS  Google Scholar 

  68. Alexiewicz JM, Kumar D, Smogorzewski M, Klin M, Massry SG. Polymorphonuclear Leukocytes in Non-Insulin-dependent Diabetes Mellitus: Abnormalities in Metabolism and Function. Ann Intern Med 1995;123(12):919–24.

    PubMed  CAS  Google Scholar 

  69. McManus LM, Bloodworth RC, Prihoda TJ, Blodgett JL, Pinckard RN. Agonist-dependent failure of neutrophil function in diabetes correlates with extent of hyperglycemia. J Leukoc Biol 2001;70(3):395–404.

    PubMed  CAS  Google Scholar 

  70. Rassias AJ, Givan AL, Marrin CAS, Whalen K, Pahl J, Yeager MP. Insulin increases neutrophil count and phagocytic capacity after cardiac surgery. Anesth Analg 2002;94(5):1113–19.

    PubMed  CAS  Google Scholar 

  71. Walrand S, Guillet C, Boirie Y, Vasson MP. In vivo evidences that insulin regulates human polymorphonuclear neutrophil functions. J Leukoc Biol 2004;76(6):1104–10.

    PubMed  CAS  Google Scholar 

  72. Artis WM, Fountain JA, Delcher HK, Jones HE. A mechanism of susceptibility to mucormycosis in diabetic ketoacidosis: transferrin and iron availability. Diabetes 1982;31(12):1109–14.

    PubMed  CAS  Google Scholar 

  73. Bhansali A, Bhadada S, Sharma A, et al. Presentation and outcome of rhino-orbital-cerebral mucormycosis in patients with diabetes. Postgrad Med J 2004;80(949):670–4.

    PubMed  CAS  Google Scholar 

  74. Jouven X, Charles MA, Desnos M, Ducimetiere P. Circulating nonesterified fatty acid level as a predictive risk factor for sudden death in the population. Circulation 2001;104(7):756–61.

    PubMed  CAS  Google Scholar 

  75. McCurdy DK. Hyperosmolar hyperglycemic nonketotic diabetic coma. Med Clin N Am 1970;54:683–99.

    PubMed  CAS  Google Scholar 

  76. Gerich JE, Martin MM, Recant L. Clinical and metabolic characteristics of hyperosmolar nonketotic coma. Diabetes 1971;20:228–38.

    PubMed  CAS  Google Scholar 

  77. Arieff AI, Carroll HJ. Nonketotic hyperosmolar coma with hyperglycemia: clinical features, pathophysiology, renal function, acid-base balance, plasma-cerebrospinal fluid equilibria and the effects of therapy in 37 cases. Medicine 1972;51:73–94.

    Google Scholar 

  78. Wachtel TJ, Silliman RA, Lamberton P. Predisposing factors for the diabetic hyperosmolar state. Arch Intern Med 1987;147:499–501.

    PubMed  CAS  Google Scholar 

  79. Wachtel TJ, Silliman RA, Lamberton P. Prognostic factors in the diabetic hyperosmolar state. J Am Geriatr Soc 1987;35(8):737–41.

    PubMed  CAS  Google Scholar 

  80. Wachtel TJ. The diabetic hyperosmolar state. Clin Geriatr Med 1990;6(4):797–806.

    PubMed  CAS  Google Scholar 

  81. Wachtel TJ, Tetu-Mouradjian LM, Goldman DL, Ellis SE, O’Sullivan PS. Hyperosmolarity and acidosis in diabetes mellitus: a three-year experience in Rhode Island. J Gen Intern Med 1991:495–502.

    Google Scholar 

  82. Piniés JA, Cairo G, Gaztambide S, Vazquez JA. Course and prognosis of 132 patients with diabetic non ketotic hyperosmolar state. Diabete & Metabolisme (Paris) 1994;20:43–8.

    Google Scholar 

  83. Delaney MF, Zisman A, Kettyle WM. Diabetic ketoacidosis and hyperglycemic hyperosmolar nonketotic syndrome. Endocrinol Metab Clin N Am 2000;29:683–705.

    CAS  Google Scholar 

  84. Gaglia JL, Wyckoff J, Abrahamson MJ. Acute hyperglycemic crisis in the elderly. Med Clin N Am 2004;88(4):1063–84, xii.

    PubMed  Google Scholar 

  85. Umpierrez GE, Kelly JP, Navarrete JE. Hyperglycemic crises in urban blacks. Arch Intern Med 1997;157:669–75.

    PubMed  CAS  Google Scholar 

  86. McCall DT, Sauaia A, Hamman RF, Reusch JE, Barton P. Are low-income elderly patients at risk for poor diabetes care? Diabetes Care 2004;27(5):1060–5.

    Google Scholar 

  87. el-Kebbi IM, Ziemer DC, Gallina DL, Dunbar V, Phillips LS. Diabetes in urban African-Americans. XV. Identification of barriers to provider adherence to management protocols. Diabetes Care 1999;22(10):1617–20.

    PubMed  CAS  Google Scholar 

  88. Cook CB, Lyles RH, El-Kebbi I, et al. The potentially poor response to outpatient diabetes care in urban African-Americans. Diabetes Care 2001;24(2):209–15.

    PubMed  CAS  Google Scholar 

  89. Emanuele N, Sacks J, Klein R, et al. Ethnicity, race, and baseline retinopathy correlates in the veterans affairs diabetes trial. Diabetes Care 2005;28(8):1954–8.

    PubMed  Google Scholar 

  90. Booth GL, Hux JE. Relationship between avoidable hospitalizations for diabetes mellitus and income level. Arch Intern Med 2003;163(1):101–6.

    PubMed  Google Scholar 

  91. Wheat L. Infection and diabetes mellitus. Diabetes Care 1980;3:187–97.

    PubMed  CAS  Google Scholar 

  92. Rayfield EJ, Ault MJ, Keusch GT, Brothers MJ, Nechemias C, Smith H. Infection and diabetes: the case for glucose control. Am J Med 1982;72:439–50.

    PubMed  CAS  Google Scholar 

  93. Leibovici L, Yehezkelli, Porter A, Regev A, Krauze I, Harell D. Influence of diabetes mellitus and glycaemic control on the characteristics and outcome of common infections. Diabet Med 1996:457–63.

    Google Scholar 

  94. Joshi N, Caputo G, Weitekamp M, Karchmer A. Infections in patients with diabetes mellitus. N Engl J Med 1999;341(25):1906–12.

    PubMed  CAS  Google Scholar 

  95. Bertoni AG, Saydah S, Brancati FL. Diabetes and the Risk of Infection-Related Mortality in the U.S. Diabetes Care 2001;24(6):1044–9.

    PubMed  CAS  Google Scholar 

  96. Shah BR, Hux JE. Quantifying the Risk of Infectious Diseases for People With Diabetes. Diabetes Care 2003;26(2):510–3.

    PubMed  Google Scholar 

  97. Davis MTE, Weerarathne T, Foong Y, Mason C, Davis WA. Community-acquired infections in type 2 diabetic patients and their nondiabetic partners. J Diabetes Complications 2005;19:259–63.

    PubMed  Google Scholar 

  98. Muller LMAJ, Gorter KJ, Hak E, et al. Increased Risk of Common Infections in Patients with Type 1 and Type 2 Diabetes Mellitus. Clin Infect Dis 2005;41(3):281–8.

    PubMed  CAS  Google Scholar 

  99. MacFarlane IA, Brown RM, Smyth RW, Burdon DW, FitzGerald MG. Bacteraemia in diabetics. J Infect 1986;12(3):213–19.

    PubMed  CAS  Google Scholar 

  100. Leibovici L, Samra Z, Konisberger H, Kalter-Leibovici O, Pitlik SD, Drucker M. Bacteremia in adult diabetic patients. Diabetes Care 1991;14(2):89–94.

    PubMed  CAS  Google Scholar 

  101. Bryan CS, Reynolds KL, Metzger WT. Bacteremia in diabetic patients: comparison of incidence and mortality with nondiabetic patients. Diabetes Care 1985;8(3):244–9.

    PubMed  CAS  Google Scholar 

  102. Thomsen RW, Hundborg HH, Lervang HH, Johnsen SP, Schonheyder HC, Sorensen HT. Risk of community-acquired pneumococcal bacteremia in patients with diabetes: a population-based case-control study. Diabetes Care 2004;27(5):1143–7.

    PubMed  Google Scholar 

  103. Thomsen RW, Hundborg HH, Lervang H-H, Johnsen SP, Sorensen HT, Schonheyder HC. Diabetes and Outcome of Community-Acquired Pneumococcal Bacteremia: A 10-year population-based cohort study. Diabetes Care 2004;27(1):70–6.

    PubMed  Google Scholar 

  104. Blitzer A, Lawson W, Meyers BR, Biller HF. Patient survival factors in paranasal sinus mucormycosis. Laryngoscope 1980;90(4):635–48.

    PubMed  CAS  Google Scholar 

  105. Doroghazi RM, Nadol JJB, Hyslop JNE, Baker AS, Axelrod L. Invasive external otitis: Report of 21 cases and review of the literature. Am J Med 1981;71(4):603.

    PubMed  CAS  Google Scholar 

  106. Sohail MA, Al Khabori M, Hyder J, Verma A. Acute fulminant fungal sinusitis: clinical presentation, radiological findings and treatment. Acta Trop 2001;80(2):177–85.

    PubMed  CAS  Google Scholar 

  107. Parikh SL, Venkatraman G, DelGaudio JM. Invasive fungal sinusitis: a 15-year review from a single institution. Am J Rhinol 2004;18(2):75–81.

    PubMed  Google Scholar 

  108. Hosseini S, Borghei P. Rhinocerebral mucormycosis: pathways of spread. Eur Arch Oto-Rhino-Laryngol 2005;262(11):932.

    Google Scholar 

  109. Taylor GW, Burt BA, Becker MP, et al. Severe periodontitis and risk for poor glycemic control in patients with non-insulin-dependent diabetes mellitus. J Periodontol 1996;67(10 Suppl):1085–93.

    PubMed  CAS  Google Scholar 

  110. Grossi SG, Skrepcinski FB, DeCaro T, et al. Treatment of periodontal disease in diabetics reduces glycated hemoglobin. J Periodontol 1997;68(8):713–19.

    PubMed  CAS  Google Scholar 

  111. Chen M-K, Wen Y-S, Chang C-C, Lee H-S, Huang M-T, Hsiao H-C. Deep neck infections in diabetic patients. Am J Otolaryngol 2000;21(3):169.

    PubMed  CAS  Google Scholar 

  112. Huang T-T, Tseng F-Y, Liu T-C, Hsu C-J, Chen Y-S. Deep neck infection in diabetic patients: Comparison of clinical picture and outcomes with nondiabetic patients. Otolaryngol - Head and Neck Surg 2005;132(6):943.

    Google Scholar 

  113. Khader YS, Dauod AS, El-Qaderi SS, Alkafajei A, Batayha WQ. Periodontal status of diabetics compared with nondiabetics: a meta-analysis. J Diabetes Complications 2006;20(1):59.

    PubMed  Google Scholar 

  114. Kinzel T, Smith M. Hyperglycemia as a predictor for mortality in veterans with pneumonia. Exp Aging Res 1988;14(2–3):99–102.

    PubMed  CAS  Google Scholar 

  115. Fine MJ, Auble TE, Yealy DM, et al. A Prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997;336(4):243–50.

    PubMed  CAS  Google Scholar 

  116. Houston MS, Silverstein MD, Suman VJ. Risk factors for 30-day mortality in elderly patients with lower respiratory tract infection. Community-based study. Arch Intern Med 1997;157(19):2190–5.

    PubMed  CAS  Google Scholar 

  117. Valdez R, Narayan KM, Geiss LS, Engelgau MM. Impact of diabetes mellitus on mortality associated with pneumonia and influenza among non-Hispanic black and white US adults. Am J Public Health 1999;89(11):1715–21.

    PubMed  CAS  Google Scholar 

  118. Falguera M, Pifarre R, Martin A, Sheikh A, Moreno A. Etiology and outcome of community-acquired pneumonia in patients with diabetes mellitus. Chest 2005;128(5):3233–9.

    PubMed  Google Scholar 

  119. McAlister FA, Majumdar SR, Blitz S, Rowe BH, Romney J, Marrie TJ. The relation between hyperglycemia and outcomes in 2,471 patients admitted to the hospital with community-acquired pneumonia. Diabetes Care 2005;28(4):810–15.

    PubMed  Google Scholar 

  120. Chu VH, Cabell CH, Benjamin DK, Jr, et al. Early predictors of in-hospital death in infective endocarditis. Circulation 2004;109(14):1745–9.

    PubMed  Google Scholar 

  121. Bishara J, Peled N, Samra Z, Sagie A, Leibovici L, Pitlik S. Infective endocarditis in diabetic and non-diabetic patients. Scand J Infect Dis 2004;36(11 –12):795.

    PubMed  Google Scholar 

  122. Huo TI, Wu JC, Lee PC, Tsay SH, Chang FY, Lee SD. Diabetes mellitus as a risk factor of liver cirrhosis in patients with chronic hepatitis B virus infection. J Clin Gastroenterol 2000;30(3):250–4.

    PubMed  CAS  Google Scholar 

  123. Huo TI, Wu JC, Lui WY, et al. Diabetes mellitus is a recurrence-independent risk factor in patients with hepatitis B virus-related hepatocellular carcinoma undergoing resection. Eur J Gastroenterol Hepatol 2003;15(11):1203–8.

    PubMed  Google Scholar 

  124. Mason AL, Lau JY, Hoang N, et al. Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology 1999;29(2):328–33.

    PubMed  CAS  Google Scholar 

  125. Arao M, Murase K, Kusakabe A, et al. Prevalence of diabetes mellitus in Japanese patients infected chronically with hepatitis C virus. J Gastroenterol 2003;38(4):355–60.

    PubMed  Google Scholar 

  126. Mehta SH, Brancati FL, Strathdee SA, et al. Hepatitis C virus infection and incident type 2 diabetes. Hepatology 2003;38(1):50–6.

    PubMed  Google Scholar 

  127. Lecube A, Hernandez C, Genesca J, Esteban JI, Jardi R, Simo R. High prevalence of glucose abnormalities in patients with hepatitis C virus infection: a multivariate analysis considering the liver injury. Diabetes Care 2004;27(5):1171–5.

    PubMed  CAS  Google Scholar 

  128. Kwon SY, Kim SS, Kwon OS, et al. Prognostic significance of glycaemic control in patients with HBV and HCV-related cirrhosis and diabetes mellitus. Diabet Med 2005;22(11):1530–5.

    PubMed  CAS  Google Scholar 

  129. Zein CO, Levy C, Basu A, Zein NN. Chronic hepatitis C and type II diabetes mellitus: a prospective cross-sectional study. Am J Gastroenterol 2005;100(1):48–55.

    PubMed  Google Scholar 

  130. Edinburgh A, Geffen A. Acute emphysematous cholecystitis: A case report and review of the world literature. Am J Surg 1958;96(1):66.

    PubMed  CAS  Google Scholar 

  131. Garcia-Sancho Tellez L, Rodriguez-Montes JA, Fernandez de Lis S, Garcia-Sancho Martin L. Acute emphysematous cholecystitis. Report of twenty cases. Hepatogastroenterology 1999;46(28):2144–8.

    PubMed  CAS  Google Scholar 

  132. Zhanel GG, Nicolle LE, Harding GK. Prevalence of asymptomatic bacteriuria and associated host factors in women with diabetes mellitus. The Manitoba Diabetic Urinary Infection Study Group. Clin Infect Dis 1995:316–22.

    Google Scholar 

  133. Geerlings SE, Stolk RP, Camps MJL, et al. Consequences of asymptomatic bacteriuria in women with diabetes mellitus. Arch Intern Med 2001;161(11):1421–7.

    PubMed  CAS  Google Scholar 

  134. Boyko EJ, Fihn SD, Scholes D, Chen C-L, Normand EH, Yarbro P. Diabetes and the risk of acute urinary tract infection among postmenopausal women. Diabetes Care 2002;25(10):1778–83.

    PubMed  Google Scholar 

  135. Foxman B, Klemstine KL, Brown PD. Acute pyelonephritis in US hospitals in 1997: hospitalization and in-hospital mortality. Ann Epidemiol 2003;13(2):144–50.

    PubMed  Google Scholar 

  136. Horcajada JP, Moreno I, Velasco M, et al. Community-acquired febrile urinary tract infection in diabetics could deserve a different management: a case-control study. J Intern Med 2003;254(3):280–6.

    PubMed  CAS  Google Scholar 

  137. Hu KK, Boyko EJ, Scholes D, et al. Risk factors for urinary tract infections in postmenopausal women. Arch Intern Med 2004;164(9):989–93.

    PubMed  Google Scholar 

  138. Boyko EJ, Fihn SD, Scholes D, Abraham L, Monsey B. Risk of urinary tract infection and asymptomatic bacteriuria among diabetic and nondiabetic postmenopausal women. Am J Epidemiol 2005;161(6):557–64.

    PubMed  Google Scholar 

  139. Scholes D, Hooton TM, Roberts PL, Gupta K, Stapleton AE, Stamm WE. Risk factors associated with acute pyelonephritis in healthy women. Ann Intern Med 2005;142(1):20–7.

    PubMed  Google Scholar 

  140. Griffin MD, Bergstralhn EJ, Larson TS. Renal papillary necrosis–a sixteen-year clinical experience. J Am Soc Nephrol 1995;6(2):248–56.

    PubMed  CAS  Google Scholar 

  141. Cook DJ, Achong MR, Dobranowski J. Emphysematous pyelonephritis. Complicated urinary tract infection in diabetes. Diabetes Care 1989;12(3):229–32.

    PubMed  CAS  Google Scholar 

  142. Wan YL, Lo SK, Bullard MJ, Chang PL, Lee TY. Predictors of outcome in emphysematous pyelonephritis. J Urol 1998:369–73.

    Google Scholar 

  143. Quint HJ, Drach GW, Rappaport WD, Hoffmann CJ. Emphysematous cystitis: a review of the spectrum of disease. J Urol 1992;147(1):134–7.

    PubMed  CAS  Google Scholar 

  144. Chow KM, Szeto CC, Leung CB, Kwan BC, Law MC, Li PK. A risk analysis of continuous ambulatory peritoneal dialysis-related peritonitis. Perit Dial Int 2005;25(4):374–9.

    PubMed  Google Scholar 

  145. Lugo-Somolinos A, Sanchez JL. Prevalence of dermatophytosis in patients with diabetes. J Am Acad Dermatol 1992;26(3 Pt 2):408–10.

    PubMed  CAS  Google Scholar 

  146. Hill LV, Tan MH, Pereira LH, Embil JA. Association of oral candidiasis with diabetic control. J Clin Pathol 1989;42(5):502–5.

    PubMed  CAS  Google Scholar 

  147. Romano G, Moretti G, Di Benedetto A, et al. Skin lesions in diabetes mellitus: prevalence and clinical correlations. Diabetes Res Clin Pract 1998;39(2):101–6.

    PubMed  CAS  Google Scholar 

  148. Romano C, Massai L, Difonzo EM. Prevalence of dermatophytic skin and nail infections in diabetic patients. Mycoses 2001;44(3–4):83–6.

    PubMed  CAS  Google Scholar 

  149. Gupta AK, Ryder JE, Chow M, Cooper EA. Dermatophytosis: the management of fungal infections. Skinmed 2005;4(5):305–10.

    PubMed  Google Scholar 

  150. Pessa ME, Howard RJ. Necrotizing fasciitis. Surg Gynecol Obstet 1985;161(4):357–61.

    PubMed  CAS  Google Scholar 

  151. Gozal D, Ziser A, Shupak A, Ariel A, Melamed Y. Necrotizing fasciitis. Arch Surg 1986;121(2):233–5.

    PubMed  CAS  Google Scholar 

  152. Kao LS, Knight MT, Lally KP, Mercer DW. The impact of diabetes in patients with necrotizing soft tissue infections. Surgical Infections 2005;6:427–38.

    PubMed  Google Scholar 

  153. Nisbet AA, Thompson IM. Impact of diabetes mellitus on the presentation and outcomes of Fournier’s gangrene. Urology 2002;60(5):775–9.

    PubMed  Google Scholar 

  154. Korkut M, Icoz G, Dayangac M, et al. Outcome analysis in patients with Fournier’s gangrene: report of 45 cases. Dis Colon Rectum 2003;46(5):649–52.

    PubMed  Google Scholar 

  155. Yeniyol CO, Suelozgen T, Arslan M, Ayder AR. Fournier’s gangrene: experience with 25 patients and use of Fournier’s gangrene severity index score. Urology 2004;64(2):218–22.

    PubMed  Google Scholar 

  156. Apelqvist J, Agardh CD. The association between clinical risk factors and outcome of diabetic foot ulcers. Diabetes Res Clin Pract 1992;18:43–53.

    PubMed  CAS  Google Scholar 

  157. Walters DP, Gatling W, Mullee MA, Hill RD. The distribution and severity of diabetic foot disease: a community study with comparison to a non-diabetic group. Diabet Med 1992;9(4):354–8.

    PubMed  CAS  Google Scholar 

  158. Currie C, Morgan C, Peters J. The epidemiology and cost of inpatient care for peripheral vascular disease, infection, neuropathy and ulceration in diabetes. Diabetes Care 1998;21(1):42–8.

    PubMed  CAS  Google Scholar 

  159. Margolis DJ, Kantor J, Berlin JA. Healing of diabetic neuropathic foot ulcers receiving standard treatment. A meta-analysis. Diabetes Care 1999;22(5):692–5.

    PubMed  CAS  Google Scholar 

  160. Mantey I, Foster AVM, Spencer S, Edmonds ME. Why do foot ulcers recur in diabetic patients? Diabetic Medicine 1999;16(3):245–9.

    PubMed  CAS  Google Scholar 

  161. Pittet D, Wyssa B, Herter-Clavel C, Kursteiner K, Vaucher J, Lew PD. Outcome of Diabetic Foot Infections Treated Conservatively: A Retrospective Cohort Study With Long-term Follow-up. Arch Intern Med 1999;159(8):851–6.

    PubMed  CAS  Google Scholar 

  162. Mantey I, Hill RL, Foster AV, Wilson S, Wade JJ, Edmonds ME. Infection of foot ulcers with Staphylococcus aureus associated with increased mortality in diabetic patients. Commun Dis Public Health 2000:288–90.

    Google Scholar 

  163. Margolis DJ, Kantor J, Santanna J, Strom BL, Berlin JA. Risk Factors for delayed healing of neuropathic diabetic foot ulcers: a pooled analysis. Arch Dermatol 2000;136(12):1531–5.

    PubMed  CAS  Google Scholar 

  164. Boulton AJM, Kirsner RS, Vileikyte L. Neuropathic Diabetic Foot Ulcers. N Engl J Med 2004;351(1):48–55.

    PubMed  CAS  Google Scholar 

  165. Falanga V. Wound healing and its impairment in the diabetic foot. Lancet 2005;366(9498):1736–43.

    PubMed  Google Scholar 

  166. Kapeller P, Fazekas F, Krametter D, et al. Pyogenic infectious spondylitis: clinical, laboratory and MRI features. Eur Neurol 1997;38(2):94–8.

    PubMed  CAS  Google Scholar 

  167. Friedman JA, Maher CO, Quast LM, McClelland RL, Ebersold MJ. Spontaneous disc space infections in adults. Surg Neurol 2002;57(2):81–6.

    PubMed  Google Scholar 

  168. Faella FS, Rossi M, Pagliano P, et al. [Non post-operative spondylodiskitis. Our experience during the period 1990–2001]. Infez Med 2002;10(3):157–62.

    PubMed  Google Scholar 

  169. Mann S, Schutze M, Sola S, Piek J. Nonspecific pyogenic spondylodiscitis: clinical manifestations, surgical treatment, and outcome in 24 patients. Neurosurg Focus 2004;17(6):E3.

    PubMed  Google Scholar 

  170. Kaandorp CJ, Van Schaardenburg D, Krijnen P, Habbema JD, van de Laar MA. Risk factors for septic arthritis in patients with joint disease. A prospective study. Arthritis Rheum 1995;38(12):1819–25.

    PubMed  CAS  Google Scholar 

  171. Durand ML, Calderwood SB, Weber DJ, et al. Acute bacterial meningitis in adults. A review of 493 episodes. N Engl J Med 1993;328(1):21–8.

    PubMed  CAS  Google Scholar 

  172. Huang CR, Lu CH, Chang HW, Lee PY, Lin MW, Chang WN. Community-acquired spontaneous bacterial meningitis in adult diabetic patients: an analysis of clinical characteristics and prognostic factors. Infection 2002;30(6):346–50.

    PubMed  CAS  Google Scholar 

  173. Idris I, Game F, Jeffcoate W. Does close glycaemic control promote healing in diabetic foot ulcers? Report of a feasibility study. Diabet Med 2005;22(8):1060–3.

    PubMed  CAS  Google Scholar 

  174. Kilby JM, Tabereaux PB. Severe hyperglycemia in an HIV clinic: preexisting versus drug-associated diabetes mellitus. J Acquir Immune Defic Syndr Hum Retrovirol 1998;17(1):46–50.

    PubMed  CAS  Google Scholar 

  175. Baker EH, Janaway CH, Philips BJ, et al. Hyperglycaemia is associated with poor outcomes in patients admitted to hospital with acute exacerbations of chronic obstructive pulmonary disease. Thorax 2006;61(4):284–9.

    PubMed  CAS  Google Scholar 

  176. Capes S, Hunt D, Malmberg K, Gerstein H. Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. Lancet 2000;355(9206):773–8.

    PubMed  CAS  Google Scholar 

  177. Bolk J, van der Ploeg T, Cornel JH, Arnold AE, Sepers J, Umans VA. Impaired glucose metabolism predicts mortality after a myocardial infarction. Int J Cardiol 2001;79(2–3):207–14.

    PubMed  CAS  Google Scholar 

  178. Foo K, Cooper J, Deaner A, et al. A single serum glucose measurement predicts adverse outcomes across the whole range of acute coronary syndromes. Heart 2003;89(5):512–16.

    PubMed  CAS  Google Scholar 

  179. Stranders I, Diamant M, van Gelder RE, et al. Admission blood glucose level as risk indicator of death after myocardial infarction in patients with and without diabetes mellitus. Arch Intern Med 2004;164(9):982–8.

    PubMed  Google Scholar 

  180. Meier JJ, Deifuss S, Klamann A, Launhardt V, Schmiegel WH, Nauck MA. Plasma glucose at hospital admission and previous metabolic control determine myocardial infarct size and survival in patients with and without type 2 diabetes: The Langendreer Myocardial Infarction and Blood Glucose in Diabetic Patients Assessment (LAMBDA). Diabetes Care 2005;28(10):2551–3.

    PubMed  Google Scholar 

  181. Nichols GA, Gullion CM, Koro CE, Ephross SA, Brown JB. The Incidence of Congestive Heart Failure in Type 2 Diabetes: An update. Diabetes Care 2004;27(8):1879–84.

    PubMed  Google Scholar 

  182. Iribarren C, Karter AJ, Go AS, et al. Glycemic Control and Heart Failure Among Adult Patients With Diabetes. Circulation 2001;103(22):2668–73.

    PubMed  CAS  Google Scholar 

  183. Bytzer P, Talley NJ, Leemon M, Young LJ, Jones MP, Horowitz M. Prevalence of Gastrointestinal Symptoms Associated With Diabetes Mellitus: A Population-Based Survey of 15 000 Adults. Arch Intern Med 2001;161(16):1989–96.

    PubMed  CAS  Google Scholar 

  184. Bytzer P, Talley NJ, Hammer J, Young LJ, Jones MP, Horowitz M. GI symptoms in diabetes mellitus are associated with both poor glycemic control and diabetic complications. Am J Gastroenterol 2002;97(3):604–11.

    PubMed  Google Scholar 

  185. Stacher G, Schernthaner G, Francesconi M, et al. Cisapride versus placebo for 8 weeks on glycemic control and gastric emptying in insulin-dependent diabetes: A Double Blind Cross-Over Trial. J Clin Endocrinol Metab 1999;84(7):2357–62.

    PubMed  CAS  Google Scholar 

  186. Bianchi G, Marchesini G, Zoli M, Bugianesi E, Fabbri A, Pisi E. Prognostic significance of diabetes in patients with cirrhosis. Hepatology 1994;20(1 Pt 1):119–25.

    PubMed  CAS  Google Scholar 

  187. Nielsen MF, Caumo A, Aagaard NK, et al. Contribution of defects in glucose uptake to carbohydrate intolerance in liver cirrhosis: assessment during physiological glucose and insulin concentrations. Am J Physiol Gastrointest Liver Physiol 2005;288(6):G1135–43.

    PubMed  Google Scholar 

  188. Jabbar MA, Zuhri-Yafi MI, Larrea J. Insulin therapy for a non-diabetic patient with severe hypertriglyceridemia. J Am Coll Nutr 1998;17(5):458–61.

    PubMed  CAS  Google Scholar 

  189. Henzen C, Rock M, Schnieper C, Heer K. [Heparin and insulin in the treatment of acute hypertriglyceridemia-induced pancreatitis]. Schweiz Med Wochenschr 1999;129(35):1242–8.

    PubMed  CAS  Google Scholar 

  190. Berger Z, Quera R, Poniachik J, Oksenberg D, Guerrero J. [Heparin and insulin treatment of acute pancreatitis caused by hypertriglyceridemia. Experience of 5 cases]. Rev Med Chil 2001;129(12):1373–8.

    PubMed  CAS  Google Scholar 

  191. Monga A, Arora A, Makkar RP, Gupta AK. Hypertriglyceridemia-induced acute pancreatitis – treatment with heparin and insulin. Indian J Gastroenterol 2003;22(3):102–3.

    PubMed  Google Scholar 

  192. Alagozlu H, Cindoruk M, Karakan T, Unal S. Heparin and Insulin in the Treatment of Hypertriglyceridemia-Induced Severe Acute Pancreatitis. Dig Dis Sci 2006.

    Google Scholar 

  193. Wu MS, Yu CC, Wu CH, Haung JY, Leu ML, Huang CC. Pre-dialysis glycemic control is an independent predictor of mortality in type II diabetic patients on continuous ambulatory peritoneal dialysis. Perit Dial Int 1999;19 Suppl 2:S179–83.

    PubMed  CAS  Google Scholar 

  194. Yu CC, Wu MS, Wu CH, et al. Predialysis glycemic control is an independent predictor of clinical outcome in type II diabetics on continuous ambulatory peritoneal dialysis. Perit Dial Int 1997;17(3):262–8.

    PubMed  CAS  Google Scholar 

  195. Davey-Smith G, Egger M, Shipley MJ, Marmot MG. Post-challenge glucose concentration, impaired glucose tolerance, diabetes, and cancer mortality in men. Am J Epidemiol 1992;136(9):1110–14.

    Google Scholar 

  196. Jee SH, Ohrr H, Sull JW, Yun JE, Ji M, Samet JM. Fasting serum glucose level and cancer risk in Korean men and women. JAMA 2005;293(2):194–202.

    PubMed  CAS  Google Scholar 

  197. Hu FB, Manson JE, Liu S, et al. Prospective study of adult onset diabetes mellitus (type 2) and risk of colorectal cancer in women. J Natl Cancer Inst 1999;91(6):542–7.

    PubMed  CAS  Google Scholar 

  198. Saydah SH, Platz EA, Rifai N, Pollak MN, Brancati FL, Helzlsouer KJ. Association of markers of insulin and glucose control with subsequent colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 2003;12(5):412–18.

    PubMed  CAS  Google Scholar 

  199. Limburg PJ, Anderson KE, Johnson TW, et al. Diabetes mellitus and subsite-specific colorectal cancer risks in the Iowa Women’s Health Study. Cancer Epidemiol Biomarkers Prev 2005;14(1):133–7.

    PubMed  Google Scholar 

  200. Gullo L, Pezzilli R, Morselli-Labate AM. Diabetes and the risk of pancreatic cancer. Italian Pancreatic Cancer Study Group. N Engl J Med 1994;331(2):81–4.

    PubMed  CAS  Google Scholar 

  201. Gapstur SM, Gann PH, Lowe W, Liu K, Colangelo L, Dyer A. Abnormal glucose metabolism and pancreatic cancer mortality. JAMA 2000;283(19):2552–8.

    PubMed  CAS  Google Scholar 

  202. Huxley R, Ansary-Moghaddam A, Berrington de Gonzalez A, Barzi F, Woodward M. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer 2005;92(11):2076–83.

    PubMed  CAS  Google Scholar 

  203. Stolzenberg-Solomon RZ, Graubard BI, Chari S, et al. Insulin, glucose, insulin resistance, and pancreatic cancer in male smokers. JAMA 2005;294(22):2872–8.

    PubMed  Google Scholar 

  204. Anderson KE, Anderson E, Mink PJ, et al. Diabetes and endometrial cancer in the Iowa women’s health study. Cancer Epidemiol Biomarkers Prev 2001;10(6):611–6.

    PubMed  CAS  Google Scholar 

  205. Augustin LS, Gallus S, Bosetti C, et al. Glycemic index and glycemic load in endometrial cancer. Int J Cancer 2003;105(3):404–7.

    PubMed  CAS  Google Scholar 

  206. Furberg AS, Thune I. Metabolic abnormalities (hypertension, hyperglycemia and overweight), lifestyle (high energy intake and physical inactivity) and endometrial cancer risk in a Norwegian cohort. Int J Cancer 2003;104(6):669–76.

    PubMed  CAS  Google Scholar 

  207. Tripathi A, Folsom AR, Anderson KE. Risk factors for urinary bladder carcinoma in postmenopausal women. The Iowa Women’s Health Study. Cancer 2002;95(11):2316–23.

    PubMed  Google Scholar 

  208. Michels KB, Solomon CG, Hu FB, et al. Type 2 diabetes and subsequent incidence of breast cancer in the Nurses’ Health Study. Diabetes Care 2003;26(6):1752–8.

    PubMed  Google Scholar 

  209. Bonovas S, Filioussi K, Tsantes A. Diabetes mellitus and risk of prostate cancer: a meta-analysis. Diabetologia 2004;47(6):1071–8.

    PubMed  CAS  Google Scholar 

  210. Chan JM, Latini DM, Cowan J, Duchane J, Carroll PR. History of diabetes, clinical features of prostate cancer, and prostate cancer recurrence-data from CaPSURE (United States). Cancer Causes Control 2005;16(7):789–97.

    PubMed  CAS  Google Scholar 

  211. Coker AL, Sanderson M, Zheng W, Fadden MK. Diabetes mellitus and prostate cancer risk among older men: population-based case-control study. Br J Cancer 2004;90(11):2171–5.

    PubMed  CAS  Google Scholar 

  212. Gonzalez-Perez A, Garcia Rodriguez LA. Prostate cancer risk among men with diabetes mellitus (Spain). Cancer Causes Control 2005;16(9):1055–8.

    PubMed  CAS  Google Scholar 

  213. Rodriguez C, Patel AV, Mondul AM, Jacobs EJ, Thun MJ, Calle EE. Diabetes and risk of prostate cancer in a prospective cohort of US men. Am J Epidemiol 2005;161(2):147–52.

    PubMed  Google Scholar 

  214. Tavani A, Gallus S, Bosetti C, et al. Diabetes and the risk of prostate cancer. Eur J Cancer Prev 2002;11(2):125–8.

    PubMed  CAS  Google Scholar 

  215. Maestu I, Pastor M, Gomez-Codina J, et al. Pretreatment prognostic factors for survival in small-cell lung cancer: a new prognostic index and validation of three known prognostic indices on 341 patients. Ann Oncol 1997;8(6):547–53.

    PubMed  CAS  Google Scholar 

  216. Meyerhardt JA, Catalano PJ, Haller DG, et al. Impact of diabetes mellitus on outcomes in patients with colon cancer. J Clin Oncol 2003;21(3):433–40.

    PubMed  Google Scholar 

  217. Saydah SH, Eberhardt MS, Loria CM, Brancati FL. Age and the Burden of Death Attributable to Diabetes in the United States. Am J Epidemiol 2002;156(8):714–9.

    PubMed  Google Scholar 

  218. Bowker SL, Majumdar SR, Veugelers P, Johnson JA. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 2006;29(2):254—8.

    PubMed  Google Scholar 

  219. Etxabe J, Vazquez JA. Morbidity and mortality in Cushing’s disease: an epidemiological approach. Clin Endocrinol (Oxf) 1994;40(4):479–84.

    CAS  Google Scholar 

  220. Colao A, Pivonello R, Spiezia S, et al. Persistence of increased cardiovascular risk in patients with Cushing’s disease after five years of successful cure. J Clin Endocrinol Metab 1999;84(8):2664–72.

    PubMed  CAS  Google Scholar 

  221. Mancini T, Kola B, Mantero F, Boscaro M, Arnaldi G. High cardiovascular risk in patients with Cushing’s syndrome according to 1999 WHO/ISH guidelines. Clin Endocrinol (Oxf) 2004;61(6):768–77.

    Google Scholar 

  222. Stenstrom G, Sjostrom L, Smith U. Diabetes mellitus in phaeochromocytoma. Fasting blood glucose levels before and after surgery in 60 patients with phaeochromocytoma. Acta Endocrinol (Copenh) 1984;106(4):511–5.

    CAS  Google Scholar 

  223. La Batide-Alanore A, Chatellier G, Plouin PF. Diabetes as a marker of pheochromocytoma in hypertensive patients. J Hypertens 2003;21(9):1703–7.

    PubMed  Google Scholar 

  224. Wiesner TD, Bluher M, Windgassen M, Paschke R. Improvement of insulin sensitivity after adrenalectomy in patients with pheochromocytoma. J Clin Endocrinol Metab 2003;88(8):3632–6.

    PubMed  CAS  Google Scholar 

  225. Holdaway IM, Rajasoorya C. Epidemiology of acromegaly. Pituitary 1999;2(1):29–41.

    PubMed  CAS  Google Scholar 

  226. Kasayama S, Otsuki M, Takagi M, et al. Impaired beta-cell function in the presence of reduced insulin sensitivity determines glucose tolerance status in acromegalic patients. Clin Endocrinol (Oxf) 2000;52(5):549–55.

    CAS  Google Scholar 

  227. Holdaway IM, Rajasoorya RC, Gamble GD. Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 2004;89(2):667–74.

    PubMed  CAS  Google Scholar 

  228. Serri O, Beauregard C, Hardy J. Long-term biochemical status and disease-related morbidity in 53 postoperative patients with acromegaly. J Clin Endocrinol Metab 2004;89(2):658–61.

    PubMed  CAS  Google Scholar 

  229. Cooppan R, Kozak GP. Hyperthyroidism and diabetes mellitus. An analysis of 70 patients. Arch Intern Med 1980;140(3):370–3.

    PubMed  CAS  Google Scholar 

  230. Sola E, Morillas C, Garzon S, Gomez-Balaguer M, Hernandez-Mijares A. Association between diabetic ketoacidosis and thyrotoxicosis. Acta Diabetol 2002;39(4):235–7.

    PubMed  CAS  Google Scholar 

  231. Baird TA, Parsons MW, Phanh T, et al. Persistent poststroke hyperglycemia is independently associated with infarct expansion and worse clinical outcome. Stroke 2003;34:2208–14.

    PubMed  CAS  Google Scholar 

  232. Levetan CS. Effect of hyperglycemia on stroke outcomes. Endocrine Practice 2004;10 (Suppl. 2):34–9.

    PubMed  Google Scholar 

  233. Gifford R, Childs BP. Diabetes care when you’re sick. Flu season is upon us. Here’s what to do when you’re feeling under the weather. Diabetes Forecast 2005;58(2):44–50.

    PubMed  Google Scholar 

  234. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999;281:2005–12.

    PubMed  CAS  Google Scholar 

  235. Wright A, Burden ACF, Paisey RB, Cull CA, Holman RR. Sulfonylurea Inadequacy: Efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). Diabetes Care 2002;25(2):330–6.

    PubMed  CAS  Google Scholar 

  236. Cook MN, Girman CJ, Stein PP, Alexander CM, Holman RR. Glycemic Control continues to deteriorate after sulfonylureas are added to metformin among patients with type 2 diabetes. Diabetes Care 2005;28(5):995–1000.

    PubMed  Google Scholar 

  237. Bethel MA, Feinglos MN. Basal insulin therapy in type 2 diabetes. J Am Board Fam Pract 2005;18(3):199–204.

    PubMed  Google Scholar 

  238. Nichols GA, Alexander CM, Girman CJ, Kamal-Bahl SJ, Brown JB. Treatment escalation and rise in hba1c following successful initial metformin therapy. Diabetes Care 2006;29(3):504–9.

    PubMed  Google Scholar 

  239. Rosenstock J, Sugimoto D, Strange P, et al. Triple Therapy in Type 2 Diabetes: Insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients. Diabetes Care 2006;29(3):554–9.

    PubMed  Google Scholar 

  240. Ratner RE, Want LL, Fineman MS, et al. Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes. Diabetes Technol Ther 2002:51–61.

    Google Scholar 

  241. Hollander PA, Levy P, Fineman MS, et al. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: A 1-year randomized controlled trial. Diabetes Care 2003;26(3):784–90.

    PubMed  CAS  Google Scholar 

  242. Buse JB, Henry RR, Han J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004;27(11):2628–35.

    PubMed  CAS  Google Scholar 

  243. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005;28(5):1092–100.

    PubMed  Google Scholar 

  244. Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005;28(5):1083–91.

    PubMed  Google Scholar 

  245. Heine RJ, Van Gaal LF, Johns D, et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: A Randomized Trial. Ann Intern Med 2005;143(8):559–69.

    PubMed  Google Scholar 

  246. Brown JB, Nichols GA, Perry A. The burden of treatment failure in type 2 diabetes. Diabetes Care 2004;27(7):1535–40.

    PubMed  Google Scholar 

  247. Dailey GE, III. Early insulin: an important therapeutic strategy. Diabetes Care 2005;28(1):220–1.

    PubMed  Google Scholar 

  248. Brown JB, Harris SB, Webster-Bogaert S, Wetmore S, Faulds C, Stewart M. The role of patient, physician and systemic factors in the management of type 2 diabetes mellitus. Fam Pract 2002;19(4):344–9.

    PubMed  Google Scholar 

  249. Ziemer DC, Doyle JP, Barnes CS, et al. An Intervention to Overcome Clinical Inertia and Improve Diabetes Mellitus Control in a Primary Care Setting: Improving Primary Care of African Americans With Diabetes (IPCAAD) 8. Arch Intern Med 2006;166(5):507–13.

    PubMed  Google Scholar 

  250. Grant RW, Buse JB, Meigs JB, for the University HealthSystem Consortium Diabetes benchmarking project T. Quality of diabetes care in U.S. Academic Medical Centers: Low rates of medical regimen change. Diabetes Care 2005;28(2):337–442.

    PubMed  Google Scholar 

  251. Taylor CB, Miller NH, Reilly KR, et al. Evaluation of a nurse-care management system to improve outcomes in patients with complicated diabetes. Diabetes Care 2003;26(4):1058–63.

    PubMed  Google Scholar 

  252. Aubert RE, Herman WH, Waters J, et al. Nurse case management to improve glycemic control in diabetic patients in a health maintenance organization: A Randomized, Controlled Trial. Ann Intern Med 1998;129(8):605–12.

    PubMed  CAS  Google Scholar 

  253. Forjuoh SN, Averitt WM, Cauthen DB, Couchman GR, Symm B, Mitchell M. Open-access appointment scheduling in family practice: comparison of a demand prediction grid with actual appointments. J Am Board Fam Pract 2001;14(4):259–65.

    PubMed  CAS  Google Scholar 

  254. Meyers ML. Changing business practices for appointing in military outpatient medical clinics: the case for a true “open access” appointment scheme for primary care. J Healthc Manag 2003;48(2):125–39.

    PubMed  Google Scholar 

  255. Pascoe SW, Neal RD, Allgar VL. Open-access versus bookable appointment systems: survey of patients attending appointments with general practitioners. Br J Gen Pract 2004;54(502):367–9.

    PubMed  Google Scholar 

  256. O’Hare CD, Corlett J. The outcomes of open-access scheduling. Fam Pract Manag 2004;11(2):35–8.

    PubMed  Google Scholar 

  257. Gandhi GY, Nuttall GA, Abel MD, et al. Intraoperative Hyperglycemia and perioperative outcomes in cardiac surgery patients. Mayo Clin Proc 2005;80:862–6.

    PubMed  Google Scholar 

  258. Shorr RI, Ray WA, Daugherty JR, Griffin MR. Individual sulfonylureas and serious hypoglycemia in older people. J Am Geriatr Soc 1996;44(7):751–5.

    PubMed  CAS  Google Scholar 

  259. Shorr RI, Ray WA, Daugherty JR, Griffin MR. Incidence and risk factors for serious hypoglycemia in older persons using insulin or sulfonylureas. Archives of Internal Medicine 1997;157(15):1681–86.

    PubMed  CAS  Google Scholar 

  260. Braithwaite S. Detection and management of diabetes mellitus during glucocorticoid therapy of nonendocrine disease. In: Meikle AW, ed. Endocrine Replacement Therapy in Clinical Practice. Totowa, N J: Humana Press, Inc; 2003:251–72.

    Google Scholar 

  261. Donihi AC, Raval D, Saul M, Korytkowski MT, DeVita MA. Prevalence and predictors of corticosteroid-related hyperglycemia in hospitalized patients. Endocrine Practice 2006;12(4):358–62.

    PubMed  Google Scholar 

  262. Clement S, Braithwaite SS, Magee MF, et al. Management of Diabetes and Hyperglycemia in Hospitals. Diabetes Care 2004;27(2):553–91.

    PubMed  Google Scholar 

  263. The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial. Diabetes 1996;45(10):1289–98.

    Google Scholar 

  264. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes 1995;44:968–83.

    Google Scholar 

  265. Ceriello A, Hanefeld M, Leiter L, et al. Postprandial Glucose Regulation and Diabetic Complications. Arch Intern Med 2004;164(19):2090–5.

    PubMed  CAS  Google Scholar 

  266. Hirsch IB, Brownlee M. Should minimal blood glucose variability become the gold standard of glycemic control? J Diabetes Complications 2005;19:178–81.

    PubMed  Google Scholar 

  267. Hirsch IB. Glycemic variability: it’s not just about A1C anymore! Diabetes Technol Ther 2005;7(5):780–3.

    PubMed  Google Scholar 

  268. Kilpatrick ES, Rigby AS, Atkin SL. The effect of glucose variability on the risk of microvascular complications in type 1 diabetes. Diabetes Care 2006;29(7):1486–90.

    PubMed  Google Scholar 

  269. Umpierrez GE, Smiley D, Zisman A, et al. Randomized Study of Basal-Bolus Insulin Therapy in the Inpatient Management of Patients With Type 2 Diabetes (RABBIT 2 Trial). Diabetes Care 2007;30(9):2181–6.

    PubMed  CAS  Google Scholar 

  270. Riddle MC, Hart JS, Bouma DJ, Phillipson BE, Youker G. Efficacy of bedtime NPH insulin with daytime sulfonylurea for subpopulation of type II diabetic subjects. Diabetes Care 1989;12:623–9.

    PubMed  CAS  Google Scholar 

  271. Bell DS, Clements RSJ, Perentesis G, Roddam R, Wagenknecht L. Dosage accuracy of self-mixed vs premixed insulin. Arch Intern Med 1991;151:2265–9.

    PubMed  CAS  Google Scholar 

  272. Coscelli C, Calabrese G, Fedele D, et al. Use of premixed insulin among the elderly. Reduction of errors in patient preparation of mixtures. Diabetes Care 1992;15(11):1628–30.

    PubMed  CAS  Google Scholar 

  273. Riddle M, Hart J, Bingham P, Garrison C, McDaniel P. Combined therapy for obese type 2 diabetes: suppertime mixed insulin with daytime sulfonylurea. Am J Med Sci 1992;303:151–6.

    PubMed  CAS  Google Scholar 

  274. Riddle M, Schneider J. Beginning insulin treatment of obese patients with evening 70/30 insulin plus glimepiride versus insulin alone. Diabetes Care 1998;21:1052–57.

    PubMed  CAS  Google Scholar 

  275. Yki-Järvinen H, Ryysy L, Nikkilä K. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus: a randomized, controlled trial. Ann Intern Med 1999;130:389–96.

    PubMed  Google Scholar 

  276. Herbst KL, Hirsch IB. Insulin strategies for primary care providers. Clin Diabetes 2002;20(1):11–17.

    Google Scholar 

  277. Riddle MC, Rosenstock J, Gerich J. The Treat-to-Target Trial: Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003;26(11):3080–6.

    PubMed  CAS  Google Scholar 

  278. Fritsche A, Schweitzer MA, Haring H-U. Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes: A Randomized, Controlled Trial. Ann Intern Med 2003;138(12):952–9.

    PubMed  CAS  Google Scholar 

  279. DeWitt DE, Hirsch IB. Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: scientific review. JAMA 2003;289(17):2254–64.

    PubMed  CAS  Google Scholar 

  280. Campbell KB, Braithwaite SS. Hospital Management of Hyperglycemia. Clin Diabetes 2004;22(2):81–8.

    Google Scholar 

  281. Magee MF, Clement S. Subcutaneous insulin therapy in the hospital setting: issues, concerns, and implementation. Endocr Pract 2004;10(Suppl. 2):81–8.

    PubMed  Google Scholar 

  282. Davies M, Storms F, Shutler S, Bianchi-Biscay M, Gomis R, for the ATLSG. Improvement of Glycemic Control in Subjects With Poorly Controlled Type 2 Diabetes: Comparison of two treatment algorithms using insulin glargine. Diabetes Care 2005;28(6):1282–8.

    PubMed  Google Scholar 

  283. Janka HU, Plewe G, Riddle MC, Kliebe-Frisch C, Schweitzer MA, Yki-Jarvinen H. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care 2005;28(2):254–9.

    PubMed  CAS  Google Scholar 

  284. Raskin P, Allen E, Hollander P, et al. Initiating Insulin Therapy in Type 2 Diabetes: A comparison of biphasic and basal insulin analogs. Diabetes Care 2005;28(2):260–5.

    PubMed  CAS  Google Scholar 

  285. Braithwaite SS. Case Study: Five steps to freedom: dose titration for type 2 diabetes using basal-prandial-correction insulin therapy. Clin Diabetes 2005;23(1):39–43.

    Google Scholar 

  286. Hirsch IB. Insulin analogues. N Engl J Med 2005;352(2):174–83.

    PubMed  CAS  Google Scholar 

  287. McCall AL. Starting insulin therapy in type 2 diabetes: lesson 1. Curr Diab Rep 2005;5(5):325–6.

    PubMed  Google Scholar 

  288. Thompson CL, Dunn KC, Menon MC, Kearns LE, Braithwaite SS. Hyperglycemia in the hospital. Diabetes Spectr 2005;18(1):20–7.

    Google Scholar 

  289. Kennedy L, Herman WH, Strange P, Harris A, for the GACT. Impact of active versus usual algorithmic titration of basal insulin and point-of-care versus laboratory measurement of hba1c on glycemic control in patients with type 2 diabetes: The Glycemic Optimization with Algorithms and Labs at Point of Care (GOAL A1C) trial. Diabetes Care 2006;29(1):1–8.

    PubMed  Google Scholar 

  290. Pearson J, Powers MA. Systematically initiating insulin: the staged diabetes management approach. Diabetes Educ 2006;32(1):19S–28.

    PubMed  Google Scholar 

  291. Leahy JL. Insulin management of diabetic patients on general medical and surgical floors. Endocr Pract 2006;12(Suppl. 3):86–90.

    PubMed  Google Scholar 

  292. Johnson MA. Carbohydrate counting for people with type 2 diabetes. Diabetes Spectr 2000;13(3):149.

    Google Scholar 

  293. Warshaw HS, Bolderman KM. Advanced carbohydrate counting. In: Practical Carbohydrate Counting: a How-to-Teach Guide for Health Professionals. Alexandria: Am Diabetes Assoc; 2001:26–8.

    Google Scholar 

  294. Fonseca V. Newly diagnosed diabetes/hyperglycemia in hospitals: what should we do? Endocr Pract 2006;12(Suppl. 3):108–11.

    PubMed  Google Scholar 

  295. Shah VP, Midha KK, Dighe S, et al. Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies. Conference report. Eur J Drug Metabol Pharmacokinetics 1991;16(4):249–55.

    CAS  Google Scholar 

  296. Yamagata H, Kiyohara Y, Nakamura S, et al. Impact of fasting plasma glucose levels on gastric cancer incidence in a general Japanese population: the Hisayama study. Diabetes Care 2005;28(4):789–94.

    PubMed  Google Scholar 

Download references

Authors
  1. Kathleen Dungan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Elizabeth Harris
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Susan S. Braithwaite
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Duke University Medical Center Durham, NC, USA

    Mark N. Feinglos MD, CM  & M. Angelyn Bethel MD  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Humana Press, a part of Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Dungan, K., Harris, E., Braithwaite, S.S. (2008). Type 2 Diabetes and Concomitant Illness. In: Feinglos, M.N., Bethel, M.A. (eds) Type 2 Diabetes Mellitus. Contemporary Endocrinology. Humana Press. https://doi.org/10.1007/978-1-60327-043-4_14

Download citation

  • DOI: https://doi.org/10.1007/978-1-60327-043-4_14

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-794-5

  • Online ISBN: 978-1-60327-043-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation